Audentes Therapeutics Inc (BOLD) Receives Average Rating of “Hold” from Brokerages
Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have been given an average recommendation of “Hold” by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $29.17.
Several analysts have weighed in on BOLD shares. Leerink Swann reaffirmed an “outperform” rating and set a $29.00 target price (up previously from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Zacks Investment Research downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Bank of America reaffirmed a “buy” rating and set a $33.00 target price (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Finally, BidaskClub downgraded Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $29.56 on Friday. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $33.43.
In other news, major shareholder Orbimed Advisors Llc sold 672,000 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $28.25, for a total value of $18,984,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. Insiders sold a total of 757,750 shares of company stock worth $21,363,350 in the last three months. Company insiders own 47.30% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of BOLD. Redmile Group LLC raised its stake in shares of Audentes Therapeutics by 77.8% in the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after buying an additional 638,780 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Audentes Therapeutics by 182.4% in the 2nd quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock worth $16,189,000 after buying an additional 546,617 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after buying an additional 383,837 shares in the last quarter. Artal Group S.A. bought a new stake in shares of Audentes Therapeutics in the 3rd quarter worth $5,602,000. Finally, State Street Corp grew its holdings in shares of Audentes Therapeutics by 231.6% in the 2nd quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock worth $4,234,000 after acquiring an additional 154,544 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.
WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/17/audentes-therapeutics-inc-bold-receives-average-rating-of-hold-from-brokerages.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.